Gastrointestinal Drugs Advisory Committee
June 26, 2000
Briefing Information
NDA 21-200, Zelmac (tegaserod) Novartis Pharmaceuticals Corporation pdf doc
Disclaimer
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document
FDA Presentation
Division of Gastrointestinal and Coagulation Drug Products, Preliminary Medical/Statistical Review pdf First 17 pages only doc